90 results
424B3
EX-31.2
CTCX
Carmell Therapeutics Corporation
16 Aug 24
Prospectus supplement
9:27am
presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls
424B3
EX-31.1
CTCX
Carmell Therapeutics Corporation
16 Aug 24
Prospectus supplement
9:27am
in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls
DEF 14A
CTCX
Carmell Therapeutics Corporation
14 Jun 24
Definitive proxy
8:24am
, including Purdue Pharma, where she was responsible for business development transactions for new therapeutic indications. Prior to Purdue, Ms. Gregory … was at Shire Pharmaceuticals and was responsible for business development transactions for the Neuroscience and Ophthalmology business units. Ms
424B3
wcwm03axs0gh7wby
5 Jun 24
Prospectus supplement
6:06am
8-K
EX-10.1
0dap2qyq04
4 Apr 24
Carmell Announces $3.0 Million Private Placement
5:28pm
8-K
EX-10.2
pl7hi
4 Apr 24
Carmell Announces $3.0 Million Private Placement
5:28pm
8-K
EX-99.1
q18tbk n0
16 Jan 24
Carmell Corp Announces Addition of Dr. Gregory A. Buford to Scientific Advisory Board
7:07pm
8-K
EX-10.1
nap2s8bablwj5g5kz su
5 Jan 24
Departure of Directors or Certain Officers
4:39pm